For the Inventor, By the Inventor

Enter inventor name

André Malanda

This inventor holds 7 USPTO granted patents and 13 EPO patents. Top assignees: Sanofi, Sanofi-Aventis. Active years: 2011-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: André Malanda. Retrieved from https://idiyas.com/inventor/andré-malanda

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7

% Patents Active = 14.3

EPO Patents = 13 (Patent Applications = 6)

Average Co-Inventor Count = 4.1

ph-index = 6

Forward Citations = 150(Granted Patents)

Company Filing History:

Years Active: 2011-2013

Loading Chart...

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8507520 - Polysubstituted 2-aryl-6-phenylimidazo[1,2-A]pyridine derivatives, and preparation and therapeutic use thereof (2013-08-13),

2. 8399491 - Derivatives of indole-2-carboxamides and of azaindole-2-carboxamides substituted with a silanyl group, preparation thereof and therapeutic use thereof (2013-03-19),

3. 8394820 - N-azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof (2013-03-12),

4. 8354425 - Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof (2013-01-15),

5. 8299114 - Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof (2012-10-30),

6. 8153650 - N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy (2012-04-10),

7. 7868024 - Derivatives of N-(heteroaryl)-1-heteroaryl-1H-indole-2-carboxamides, preparation thereof and therapeutic use thereof (2011-01-11),

Sure, I will write the article about inventor André Malanda. Just a moment please.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…